Gurnet Point Capital and Patient Square Capital are buying biopharmaceutical company Radius Health for $890 million. Radius shareholders will receive $10 per share. Also, if abaloparatide reaches $300 million in TTM sales by December 31, 2025, shareholders will receive another $1 for each share. The transaction is expected to close in Q3 2022.